-- Commercial employees (non-executive) who were hired specifically for the launch of ROLVEDON (eflapegrastim-xnst) injection are the recipients of this grant --
BOSTON, December 27, 2022--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that on December 27, 2022, Spectrum’s Board of Directors granted an aggregate of 206,059 inducement restricted stock units ("RSUs") to commercial non-executive employees who were hired specifically for the launch of ROLVEDON. The awards were granted under Spectrum’s 2022 Employment Inducement Incentive Award Plan ("Inducement Plan") as employment inducement awards pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Spectrum, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Spectrum, pursuant to Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over three years on the first three anniversaries of the grant date, subject to continued service through each applicable vesting date.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the...
The woman who accused Jay-Z of raping her when she was 13 years old has fully recanted her allegations, and apologised for the “immense pain” she caused the rapper and his family, including wife B...